Engineered genetic solutions for combating infectious ailments

The 'AGEnTS' project, led by Dr. Kilian Schober at Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), is making strides in the field of immunotherapy. The research focuses on genetic engineering of T-cells for treating infectious diseases, particularly those that have developed drug resistance.

Dr. Schober's team is working on modifying T-cells, a specific type of immune cell, for potential use in individuals with a suppressed immune system. The primary goal is to combat drug-resistant pathogens using genetically modified immune cells.

The current method of transferring natural T-cells is complicated, expensive, and requires tailoring for each individual patient. However, the 'AGEnTS' project aims to revolutionise this process by employing CRISPR-Cas9 gene editing technology. This technology is expected to make the treatment process less complex and expensive.

The modified T-cells, designed to remain similar to natural cells, are intended for individuals who are at risk of fatal infections with herpes viruses. The researchers hope that these cells will help combat herpes viruses that have become resistant to medication.

The Federal Ministry of Education and Research is providing 2,162,188 euros in funding for the 'AGEnTS' project from 2021 to 2026. The project's aim is to develop a treatment that can be used on a wider range of patients, potentially leading to the development of treatments for a variety of drug-resistant infectious diseases.

In the long term, this type of treatment may be used to treat other infectious diseases with drug-resistant pathogens. The researchers at FAU plan to strengthen the immune system of these individuals using physiologically modified cells.

The 'AGEnTS' project is being conducted at Friedrich-Alexander University Erlangen-Nürnberg (FAU) and is focused on treating infectious diseases, with a specific emphasis on drug-resistant pathogens and herpes viruses. The team's ultimate goal is to provide a more accessible and effective solution for combating drug-resistant pathogens and improving the lives of those at risk of these devastating infections.